New scan test for scarring in blood cancers
Part of Blood & lymphatic clinical trials.
This study tests a new way to detect scar tissue in the bone marrow using a special scan and blood test. It might help doctors see how your disease is changing without needing a bone marrow biopsy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of essential thrombocythemia, polycythemia vera, pre-fibrotic primary myelofibrosis, overt primary myelofibrosis, or secondary myelofibrosis.
- You must be 18 years or older.
- You must be well enough to be up and about more than half the day (ECOG 0-3).
- If you are having the PET scan, you cannot have taken cytoreductive drugs (like hydroxyurea) in the last 3 months.
- You cannot be pregnant or breastfeeding.
- You cannot be currently taking JAK inhibitors (like ruxolitinib) or interferon.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental pill called PRT12396 for people with myeloproliferative neoplasms (MPN). It aims to see if the drug is safe and helps control the disease.
This trial tests an experimental drug called PMD-026 for people with myelofibrosis that has not responded well to a JAK inhibitor (like ruxolitinib). The goal is to see if PMD-026 can help reduce symptoms and spleen size.
This trial tests whether a special type of PET scan (using a tracer called 18F-FAPI) can see myelofibrosis activity better than standard scans. It may help doctors track the disease more accurately without needing extra biopsies.
This study uses a new type of PET/CT scan with a tracer called 68Ga-FAPI to help diagnose myelofibrosis, see how advanced it is, and check if treatment is working. It may help doctors better understand your condition and plan your care.
This study looks at whether a simple blood test can give the same information as a bone marrow biopsy for people with myeloproliferative neoplasms (MPNs), which are blood cancers that cause the bone marrow to make too many cells. If successful, it could mean less invasive testing for patients.
This trial tests a new drug, INCA035784, for people with myeloproliferative neoplasms (MPNs), a group of blood cancers. It may help if your MPN is called myelofibrosis (MF) or essential thrombocythemia (ET) and has a specific genetic change (CALR mutation), and you've already tried other treatments.
Hear when a new Myelofibrosis (MF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.